These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 11928574)

  • 1. [Inhibition of bone resorption by bisphosphonates, heterogeneous group of drugs with different intracellular model of action].
    Stajszczyk M
    Pol Arch Med Wewn; 2001 Jul; 106(1):617-29. PubMed ID: 11928574
    [No Abstract]   [Full Text] [Related]  

  • 2. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates.
    Dunford JE; Thompson K; Coxon FP; Luckman SP; Hahn FM; Poulter CD; Ebetino FH; Rogers MJ
    J Pharmacol Exp Ther; 2001 Feb; 296(2):235-42. PubMed ID: 11160603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nitrogen-containing bisphosphonate mechanism of action.
    Reszka AA; Rodan GA
    Mini Rev Med Chem; 2004 Sep; 4(7):711-9. PubMed ID: 15379639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.
    Rogers MJ
    Calcif Tissue Int; 2004 Dec; 75(6):451-61. PubMed ID: 15332174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular and molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Gordon S; Benford HL; Coxon FP; Luckman SP; Monkkonen J; Frith JC
    Cancer; 2000 Jun; 88(12 Suppl):2961-78. PubMed ID: 10898340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular targets of the nitrogen containing bisphosphonates: the molecular pharmacology of prenyl synthase inhibition.
    Dunford JE
    Curr Pharm Des; 2010; 16(27):2961-9. PubMed ID: 20722615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyridinium-1-yl bisphosphonates are potent inhibitors of farnesyl diphosphate synthase and bone resorption.
    Sanders JM; Song Y; Chan JM; Zhang Y; Jennings S; Kosztowski T; Odeh S; Flessner R; Schwerdtfeger C; Kotsikorou E; Meints GA; Gómez AO; González-Pacanowska D; Raker AM; Wang H; van Beek ER; Papapoulos SE; Morita CT; Oldfield E
    J Med Chem; 2005 Apr; 48(8):2957-63. PubMed ID: 15828834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular mechanisms of action of bisphosphonates.
    Rogers MJ; Frith JC; Luckman SP; Coxon FP; Benford HL; Mönkkönen J; Auriola S; Chilton KM; Russell RG
    Bone; 1999 May; 24(5 Suppl):73S-79S. PubMed ID: 10321934
    [No Abstract]   [Full Text] [Related]  

  • 9. New insights into the molecular mechanisms of action of bisphosphonates.
    Rogers MJ
    Curr Pharm Des; 2003; 9(32):2643-58. PubMed ID: 14529538
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bisphosphonates and primary hyperparathyroidism.
    Rodan GA
    J Bone Miner Res; 2002 Nov; 17 Suppl 2():N150-3. PubMed ID: 12412793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular mechanisms of action of bisphosphonates and strontium ranelate].
    Vengerovskiĭ AI; Khlusov IA; Nechaev KA
    Eksp Klin Farmakol; 2014; 77(9):43-6. PubMed ID: 25365870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase.
    Bergstrom JD; Bostedor RG; Masarachia PJ; Reszka AA; Rodan G
    Arch Biochem Biophys; 2000 Jan; 373(1):231-41. PubMed ID: 10620343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo effects of bisphosphonates on the osteoclast mevalonate pathway.
    Fisher JE; Rodan GA; Reszka AA
    Endocrinology; 2000 Dec; 141(12):4793-6. PubMed ID: 11108295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase.
    Thompson K; Dunford JE; Ebetino FH; Rogers MJ
    Biochem Biophys Res Commun; 2002 Jan; 290(2):869-73. PubMed ID: 11785983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of geranylgeranylation in bone resorption and its suppression by bisphosphonates in fetal bone explants in vitro: A clue to the mechanism of action of nitrogen-containing bisphosphonates.
    van beek E; Löwik C; van der Pluijm G; Papapoulos S
    J Bone Miner Res; 1999 May; 14(5):722-9. PubMed ID: 10320520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An investigation of bone resorption and Dictyostelium discoideum growth inhibition by bisphosphonate drugs.
    Szabo CM; Martin MB; Oldfield E
    J Med Chem; 2002 Jul; 45(14):2894-903. PubMed ID: 12086477
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of bisphosphonates.
    Rogers MJ; Watts DJ; Russell RG
    Cancer; 1997 Oct; 80(8 Suppl):1652-60. PubMed ID: 9362432
    [No Abstract]   [Full Text] [Related]  

  • 18. A novel inhibitory mechanism of nitrogen-containing bisphosphonate on the activity of Cl- extrusion in osteoclasts.
    Ohgi K; Kajiya H; Okamoto F; Nagaoka Y; Onitsuka T; Nagai A; Sakagami R; Okabe K
    Naunyn Schmiedebergs Arch Pharmacol; 2013 Jul; 386(7):589-98. PubMed ID: 23564016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphonocarboxylate inhibitors of Rab geranylgeranyl transferase disrupt the prenylation and membrane localization of Rab proteins in osteoclasts in vitro and in vivo.
    Coxon FP; Ebetino FH; Mules EH; Seabra MC; McKenna CE; Rogers MJ
    Bone; 2005 Sep; 37(3):349-58. PubMed ID: 16006204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JBMR anniversary classic. Nitrogen-containing biophosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. Originally published in Volume 7, number 4, pp 581-9 (1998).
    Luckman SP; Hughes DE; Coxon FP; Russell GG; Rogers MJ
    J Bone Miner Res; 2005 Jul; 20(7):1265-74. PubMed ID: 16050006
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.